Clinical Trials in Arizona

Showing 8881-8900 of 14,395 trials

A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors

NCT02743637

This is a Phase 1 dose escalation to assess the safety, tolerability and maximum tolerated dose of subcutaneous administered SDX-7320 in patients with advanced refractory or late-stage solid tumors.

Advanced MalignancyAdvanced Solid TumorsNeoplasm+1 more

SynDevRx, Inc.32 participantsStarted Feb 2016

Scottsdale, Arizona, United States • Los Angeles, California, United States • Nashville, Tennessee, United States

COMPLETEDPhase 231 miles

Rituximab, Pentostatin, Cyclophosphamide, and Lenalidomide in Treating Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT00602836

RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy, such as pentostatin and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Lenalidomide may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving rituximab together with combination chemotherapy and lenalidomide may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving rituximab together with pentostatin, cyclophosphamide, and lenalidomide works in treating patients with previously untreated B-cell chronic lymphocytic leukemia or small lymphocytic lymphoma.

LeukemiaLymphoma

Mayo Clinic45 participantsStarted Feb 2008

Scottsdale, Arizona, United States • Jacksonville, Florida, United States • Rochester, Minnesota, United States

A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors

Rituximab, Pentostatin, Cyclophosphamide, and Lenalidomide in Treating Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Find Trials by Condition in Arizona

Lacripep™ in Subjects With Dry Eye Associated With Primary Sjögren's Syndrome

Opioid-induced Bowel Dysfunction: Long-Term Assessment of Lubiprostone

Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

A Study to Evaluate a Potassium Normalization Treatment Regimen Including Sodium Zirconium Cyclosilicate (ZS) Among Patients With S-K ≥5.8

Lubiprostone for Children With Constipation

Severe ARDS: Generating Evidence

Dasotraline Pediatric Extension Study

First in Patient Study for PF-06840003 in Malignant Gliomas

Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis

A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma

A Study of Obinutuzumab to Evaluate Safety and Tolerability in Hypersensitized Adult Participants With End Stage Renal Disease Awaiting Transplantation

Vitamin D to Improve Outcomes by Leveraging Early Treatment

SVRII Family Factors Study

Study to Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S in Participants With Staphylococcus Aureus Bacteremia Receiving Standard-of-Care (SOC) Antibiotics

Frozen Red Blood Cell Transfusions in Trauma Patients

DELTA Trial: Does Embolization With Larger Coils Lead to Better Treatment of Aneurysms Trial